Neal is a highly accomplished operator with deep experience in healthcare, IT and big data. Prior to joining Target RWE, Neal served as President and CEO of Symphony Health Solutions, a leading real-world health data, analytics and software which was acquired by PRA Health Sciences in 2017. He assembled and led a team that successfully transformed the business into a high growth technology and data analytics platform.
Prior to Symphony Health, Neal held executive leadership roles at various healthcare solutions businesses, including Focus Diagnostics (Quest Diagnostics) and IMS Health (IQVIA). He attended Dartmouth College and Dartmouth’s Tuck School of Business Administration.
Michael W. Fried, MD, FAASLD
Co-Founder & Chief Medical Officer
Michael W. Fried, MD, FAASLD, co-founder and Chief Medical Officer for Target RWE, is Professor of Medicine in the Division of GI and Hepatology at the University of North Carolina at Chapel Hill. Dr. Fried completed his internship and residency in internal medicine at the State University of New York (SUNY) Health Science Center at Syracuse, where he also completed a fellowship in gastroenterology.
From 1990 to 1993, while serving as Medical Staff Fellow in the Liver Diseases Section at the National Institutes of Health (NIH) in Bethesda, Maryland, Dr. Fried performed clinical and laboratory studies of viral hepatitis. During his tenure at UNC, he has been the principal investigator on numerous phase I, II, and III clinical trials of antiviral agents for chronic hepatitis B and hepatitis C. Dr. Fried has been awarded continuous NIH extramural funding for more than 20 years as principal investigator on multiple NIH cooperative clinical trials, including as current co-Chair of the NIH Hepatitis B Research Network.
Dr. Fried is co-principal investigator of the HCV-TARGET international network of investigators to study the real-world experience with therapies for hepatitis C. Dr. Fried and HCV-TARGET colleagues were awarded the Regulatory Science Excellence Award by the FDA in 2018 for their contributions of real-world evidence regarding the safety and effectiveness of hepatitis C therapeutics.
Dr. Fried is the primary author or co-author on over 200 original publications, reviews, and book chapters concentrated in the field of viral hepatitis. His manuscript on therapy of hepatitis C, published in 2002, established the standard of care for this disease for more than a decade and was one of the most highly cited publications in the field of gastroenterology.
Dr. Fried served on the Governing Board of the American Association for the Study of Liver Diseases (AASLD) and was the president of AASLD in 2019.
Chief Business Officer
Matt Casbon is currently serving as Chief Business Officer for Target RWE Health Evidence Solutions. Prior to joining Target RWE, Matt was Senior Vice President of Global Strategic Marketing at Circassia where he was responsible for global research sales, global marketing, and training.
Prior to Circassia, Matt worked as the Vice President of Marketing at KemPharm. Matt also previously worked at Chimerix, Salix Pharmaceuticals, Abbott Laboratories, and Solvay Pharmaceuticals in various roles of increasing responsibility. He brings over 25 years of business development, sales and marketing experience, including strategic partnerships, pre-commercial strategy planning, product launches, and sales force operations. Matt received his BA from the West Chester University.
Senior Vice President, Clinical Operations
Laura Malahias has over 13 years of experience working in clinical research including assignments on all sides of the industry from study site, small and large CROs, to pharma. She is currently serving as Senior Vice President of Clinical Operations at Target RWE Health Evidence Solutions. Prior to her work at Target RWE, Laura worked at Aerial BioPharma where she played an integral role in the development of ADX-N05 (Solriamfetol) which was sold to Jazz Pharmaceuticals.
Vice President, Enterprise Architecture
Viswa has more than 19 years of proven experience spanning analytics, machine learning, application development, and software engineering. Most recently, he served as VP of Architecture and R&D at Symphony Health Solutions where he architected and built various machine learning and analytics toolsets.
In his past experience, Viswa has designed and developed several complex systems including “The (Microbiology) Surveillance Network”, Electronic Lab, and Clinical Analytics Architecture framework.
Viswa earned his degree in electrical engineering; however, his professional experience has focused on healthcare and life sciences.
Vice President, Technology
Jason Fox is currently serving as Vice President of Technology at Target RWE.
Jason has over 15 years’ experience in software engineering and architecture, including stints at NASA’s Jet Propulsion Laboratory and SAS. Jason is an expert in building high performing, highly available software systems for a wide array of industries. Whether it is mission support software for robotic exploration of Mars, or scalable frameworks for high-end analytics, Jason brings his methodical approach and deep understanding of computer systems to solving difficult problems.
Jason received his Master’s degree in Computer Science from Purdue University and his Bachelors in Computer Science Engineering from The Ohio State University.
Vice President, Finance
Jennifer (Jen) Woods is currently serving as Vice President of Finance for Target RWE. Jen has over 15 years of experience in the accounting and finance industry serving a variety of sectors, including life sciences, telecommunications, and banking. Before joining Target RWE, Jen held various positions at Ernst & Young, LLP, the American Institute of CPAs, and Wachovia Bank. Most recently, she served in accounting and finance roles for private companies and non-profits. Jen is a client-focused, team player with strong communication skills and a proven track record of managing assignments and directing teams of professionals to produce results.
Vice President, Compliance and Legal Affairs
Allison joined Target RWE in January 2018 where she previously served as Senior Director of Legal Affairs and is now serving as Vice President, Compliance and Legal Affairs. Her experience includes serving as Assistant General Counsel of the Oklahoma Corporation Commission, various legal consulting roles, and most recently before Target RWE, managing contracts and regulatory operations in site start-up for clinical trials with Syneos Health. Outside of work, Allison enjoys spending time with her husband and three children.
Senior Director, Human Resources
Melissa is currently serving as Senior Director of Human Resources at Target RWE. Melissa Mulauski has over 18 years of human resources experience in employee relations, training, policy development, compensation, and recruiting.
Melissa spent 6 years working at Quintiles in their Human Resources department and another 3 years heading the Human Resources department at Peopleclick before joining Strategic HR Solutions as a Consultant.
Melissa is professionally certified as a Senior Professional in Human Resources (SPHR) and also as a SHRM Senior Certified Professional (SCP). She holds a Bachelor of Science degree in Labor and Industrial Relations with a Business minor from The Pennsylvania State University.
Senior Vice President, Commercial
Brian joins Target RWE after 17+ highly successful years in commercial leadership roles at Symphony Health Solutions where he most recently served as Senior Vice President of Business Development. In this role, Brian led the commercial activities for both the company’s sales and consulting organizations. Prior to leading the commercial team, Brian served as Senior Vice President of Health Data Alliances where he was responsible for data acquisition, supplier relations and industry partnerships.
Brian has additionally held previous leadership roles across various customer segments and geographic territories throughout his career, focusing on sales and business development. Brian received his Bachelor of Business Administration degree from the University of Notre Dame.
Meg Powell, PharmD, MBA
Co-Founder and Board Chair
Meg Powell has over 15 years of experience in the pharmaceutical industry including assignments at McKinsey, Eli Lilly and GlaxoSmithKline. She is currently serving as Board Chair and is the Co-Founder of Target RWE.
Meg has worked with multiple start-up companies while at Medgility, a consulting firm focused on strategy and business development of emerging companies. These include Qura Therapeutics, KemPharm, Inc, and most notably, Aerial Biopharma where she was the Interim VP of Corporate Development and was instrumental in the sale of ADX-N05 to Jazz Pharmaceuticals.
Prior to her work at Medgility, Meg was Vice President of the US Transformation Office at GlaxoSmithKline. She has in depth experience in sales and marketing for US and global development programs at all stages – from phase 1 to post patent expiry.
Meg received her Doctorate of Pharmacy degree from the University of North Carolina- Chapel Hill where she was a Hollingsworth Scholar. She also received a Master’s of Business Administration from Stanford University.
Eric Edell is Co-Founder and Co-Managing Partner of 22C Capital, a private equity firm committed to delivering capital and critical resources to companies operating at the intersection of technology enablement and data analytics adoption. The Firm has a dedicated focus on the healthcare services, business services, and financial services sectors. 22C's operational and technology resources, including its affiliated data science organization strive to deliver practical, real-world support to help convert these businesses' challenges into opportunities and unlock their full potential.
Mr. Edell received his B.A. in Neuroscience, summa cum laude, from the University of Pennsylvania, where he was a member of Phi Beta Kappa. He lives in New York City with his wife, Deborah, and their three children.
Ryan A. Harris, MD
Ryan Harris, MD brings more than twenty-five years of healthcare experience and fifteen years as a growth equity and buyout investor. Combining deep medical knowledge and extensive strategic business experience, Ryan focuses on growth equity investments in the healthcare sector in Norwest’s Palo Alto office. Areas in which he invests include healthcare services, pharma services, healthcare IT, medical devices. Ryan’s current investments include Blue Cloud, Onsite Dental, and Rivermend Health. His previous investments include Capsugel (acquired by Lonza), Crossover Health (acquired by Gurnet Point Capital), and iCardiac (acquired by ERT).
Prior to joining Norwest, Ryan was a Principal with The Carlyle Group and a Venture Partner with Industry Ventures, where he focused exclusively on healthcare services, pharmaceutical, and medical device investments from large cap buyouts to growth equity and venture.
At Carlyle, Ryan’s deals led to realized profitable exits of more than $2.2 billion equity value. He served as a member or observer on the Board of Directors of Align Technologies (Nasdaq: ALGN), AqueSys, Colin Medical, ConnectiCare, MedPointe Pharmaceuticals, Multiplan, NeoVista, Proteus Biomedical and Qualicaps.
At Industry Ventures, Ryan executed transactions involving Access Closure, Cardiofocus, Ingenuity, and Intarcia. Prior to joining Carlyle in 2002, Ryan was a consultant in the West Coast Healthcare Practice of McKinsey & Company, where he worked with a variety of biotechnology, pharmaceutical and medical device companies on corporate, R&D and marketing strategies.
Ryan has authored more than 25 peer-reviewed comparative effectiveness articles in publications such as JAMA, Lancet, Annals of Internal Medicine, and the Journal of Health Economics.
Dr. Harris holds an M.D. from the University of California, San Francisco, School of Medicine. In addition, he earned an M.S. in health research and policy, and a B.A. in psychology from Stanford University. Ryan also attended Oxford University’s Magdalen College.
Franz Humer, PhD
Dr. Humer is Chairman of the Board of Directors of the International Centre for Missing & Exploited Children and Chairman of the Humer Foundation. He is also a Non-Executive Director of the Board at Allogene Therapeutics, the Chairman of PCI Services and an Advisor to Temasek Holdings and Letterone Healthcare.
Before joining Roche Group, he was the managing director of Glaxo Pharmaceuticals UK Ltd. and was elected to the Board of Glaxo Holdings plc where he progressed to be responsible for research, business development, manufacturing, commercial strategy, and all non-U.S. operations for 13 years. In 1973, Franz joined Schering-Plough Corporation, where he held various general management positions in Latin America and Europe. In 1995, he joined Hoffmann-La Roche as a member of its Board and the head of its pharmaceuticals division, becoming Chairman and CEO in 2001 and Chairman of Roche Holding Limited between 2008 and 2014. Franz joined the Board of Diageo in 2005, became Chairman in 2008 and retired in 2016. Franz earned a PhD in law from the University of Innsbruck and an MBA from INSEAD in Fontainbleau, France.